You need to download the latest flash player - download it here

  • About Us
    • Management Team
    • Board of Directors
    • Personalized Medicine
  • Products
    • OMAPRO™ (omacetaxine mepesuccinate)
    • Quinamed® (amonafide dihydrochloride)
  • Research and Development
    • Drug Discovery & Preclinical Development
    • Genomic Clinical Development
  • Investors
    • Financial Reports
    • Presentations
    • Corporate Governance
    • Analyst Coverage
    • Information Requests
  • News, Media & Events
    • Recent Press Releases
    • Press Release Archive
    • Media Contact
  • Clinical Trials
    • Chronic Myelogenous Leukemia
    • Myelodysplastic Syndrome
    • Solid Cancers
  • Careers
    • Culture
    • Current Openings
  • Recent Press Releases
  • Press Release Archive
  • Media Contact

Recent Press Releases


March 2nd, 2010

U.S. Food and Drug Administration (FDA) Sets 22 March for Oncologic Drugs Advisory Committee (ODAC) Meeting to Review OMAPRO™

February 9th, 2010

Extreme Weather in Washington D.C. has Postponed the FDA’s Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010

December 17th, 2009

ChemGenex Pharmaceuticals Announces Omapro™ to be Reviewed by the FDA’s Oncologic Drugs Advisory Committee

December 14th, 2009

ChemGenex, Hospira, Announce Agreement to License, Develop and Commercialize Leukemia Drug in Europe

December 9th, 2009

Omapro™ Featured During ASH Oral Session

December 7th, 2009

Pivotal Data on ChemGenex’s Omapro™ Highlighted at ASH Press Conference

November 27th, 2009

ChemGenex’s Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency

November 10th, 2009

ChemGenex Announces FDA Accepts NDA for Omapro™ (Omacetaxine Mepesuccinate) and Grants the Filing Priority Review Status

October 28th, 2009

Chemgenex CEO Receives Ausbiotech Award

September 9th, 2009

ChemGenex Submits New Drug Application for OMAPRO™ (Omacetaxine Mepesuccinate) to U.S. FDA

Home Contact Us Sitemap

© 2010 ChemGenex Pharmaceuticals

Terms of Use